SABCS: Omission of Axillary Staging Noninferior for Node-Negative Breast Cancer
By Elana Gotkine HealthDay Reporter
FRIDAY, Dec. 13, 2024 -- Omission of surgical axillary staging is noninferior to sentinel-lymph-node biopsy for patients with clinically node-negative, T1 or T2 invasive breast cancer, according to a study published online Dec. 12 in the New England Journal of Medicine to coincide with the annual San Antonio Breast Cancer Symposium, held from Dec. 10 to 13 in San Antonio.
Toralf Reimer, Ph.D., from the University of Rostock in Germany, and colleagues conducted a prospective, randomized, noninferiority trial to examine omission of axillary surgery compared with sentinel-lymph-node biopsy in patients with clinically node-negative breast cancer (stages T1 or T2) who were scheduled to undergo breast-conserving surgery. The primary efficacy outcome was per-protocol analysis of invasive disease-free survival. The five-year invasive disease-free survival rate had to be at least 85 percent to show noninferiority, and the upper limit of the confidence interval for the hazard ratio for invasive disease or death had to be below 1.271.
A total of 5,502 eligible patients were randomly assigned in a 1:4 ratio. The per-protocol population comprised 4,858 patients: 962 were assigned to undergo treatment without axillary surgery (surgery-omission group) and 3,896 were assigned to sentinel-lymph-node biopsy (surgery group). Patients were followed for a median of 73.6 months. The researchers found that the estimated five-year invasive disease-free survival rate was 91.9 and 91.7 percent among patients in the surgery-omission and surgery groups, respectively (hazard ratio, 0.91; 95 percent confidence interval, 0.73 to 1.14), meeting noninferiority.
"The omission of axillary sentinel-lymph-node biopsy does not compromise survival in patients with early-stage, cN0 breast cancer who plan to undergo primary breast-conserving surgery," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
Socioeconomic Deprivation Tied to Neurodegeneration in Combat Athletes
THURSDAY, Aug. 14, 2025 -- Athletes experiencing early-life socioeconomic disadvantage may have an increased risk for neurodegeneration from exposure to repetitive head injury...
ADHD Drug Treatment Linked to Reduced Rate of Adverse Outcomes
THURSDAY, Aug. 14, 2025 -- Attention-deficit/hyperactivity disorder (ADHD) drug treatment is associated with reduced rates of adverse outcome events, including suicidality...
2009 to 2023 Saw Increase in Use of Technology, Glycemic Control in Type 1 Diabetes
THURSDAY, Aug. 14, 2025 -- From 2009 to 2023, there was an increase in use of diabetes technology and in glycemic control among youths and adults with type 1 diabetes (T1D)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.